Year: 2021

VANCOUVER, British Columbia, Nov. 26, 2021 (GLOBE NEWSWIRE) — Uniserve Communications Corporation (the “Company” or “Uniserve”) is pleased to announce that it held its Annual General Meeting on Thursday, November 18, 2021, whereat Messrs. Earnest C. Beaudin, Kelly Walker, Walter Schultz, Owen Morley, and Stuart Omsen were re-appointed to the Company’s Board of Directors, and Mr. Arif Merali was appointed as a member of its Board for the ensuing year. Uniserve continues to successfully shift the focus of its revenue generating activities to a contractual recurring model. Over the recent months, Uniserve has been proud to launch a number of new products to its customers including Uniserve Hyperconverged (UHC), Uniserve Firewall as a Service (FaaS), Uniserve DR as a Service (DRaaS) and has continued the expansion of its Infrastructure...

Figure 1: Peranggih Location Map showing interpreted mineralizationFigure 1: Peranggih Location Map showing interpreted mineralizationFigure 2: Drill hole locations and geological map of PeranggihFigure 2: Drill hole locations and geological map of PeranggihFigure 3: The N-S long section of Peranggih shows the high-grade interception from the RC drilling programFigure 3: The N-S long section of Peranggih shows the high-grade interception from the RC drilling programVANCOUVER, British Columbia, Nov. 26, 2021 (GLOBE NEWSWIRE) — Monument Mining Limited (TSX-V: MMY and FSE: D7Q1) (“Monument” or the “Company”) is pleased to announce drill results from the reverse circulation (“RC”) drilling program at South and Central areas of the Peranggih Gold Prospect (“Peranggih”),...

WAYNE, Pa., Nov. 26, 2021 (GLOBE NEWSWIRE) — Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies for critical care and surgery, has announced a worldwide recall of Arrow-Trerotola™ Over-The-Wire PTD® Kit Percutaneous Thrombolytic Device: 7FR. The Arrow-Trerotola Percutaneous Thrombolytic Device (PTD) Catheter, in conjunction with the Arrow Rotator Drive Unit, permits mechanical declotting of native arterio-venous (AV) fistulae and synthetic dialysis grafts. The products involved in the recall are as follows. Additional detail about how to identify the affected products is available in the recall letter.Product Code Lot Number Unique Device Identifier (UDI) #PT-12709-WC 13F19K0564 (01)20801902156758 (17)210930 (10)13F19K056413F20C0094 (01)10801902121254 (17)220228 (10)13F20C009413F20G0284 (01)10801902121254...

GENEVA, Nov. 26, 2021 (GLOBE NEWSWIRE) — Etrion Corporation (“Etrion” or the “Company”) (OMX: ETX) announces that following the recent sale of all the Company’s solar assets and the return of capital to shareholders, Henrika Frykman will be stepping down from the Board of Directors effective November 30th, 2021. Aksel Azrak, Chairman of the Board, commented, “On behalf of the Board members I want to take this opportunity to thank Henrika for her invaluable leadership and contributions as a board member for the past three years.” About Etrion The Company is listed on the Nasdaq Stockholm exchange in Sweden under ticker symbol “ETX”. Etrion’s largest shareholder is the Lundin family, which owns approximately 36% of the Company’s shares directly and through various trusts. For additional information, please visit the Company’s website...

TORONTO, Nov. 26, 2021 (GLOBE NEWSWIRE) — Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company with a focus on natural psychedelics in mental health and well-being, announces that the Unaudited Condensed Consolidated Interim Financial Statements for the six months period ended September 30, 2021 and Management Discussion & Analysis (“MD&A”) for the three months ended September 30, 2021 will be filed on November 29, 2021. As a result of a continuous disclosure review conducted by Staff of the Ontario Securities Commission, the Company has included enhanced disclosure in its MD&A relating to, among other things, liquidity and cash resources, discussion of operations, its projects, expenditures made, and the timing and costs anticipated to advance the Company’s...

SOUTH SAN FRANCISCO, Nov. 26, 2021 (GLOBE NEWSWIRE) — Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will participate in a fireside chat at the Evercore ISI 4th Annual HealthCONx Virtual Conference on Thursday December 2 at 3:30 p.m. E.T. A live webcast of the Company fireside chat will be available through the investor relations section of the Company’s website at www.akerotx.com. Following the live webcasts, archived replays will be available on the Company’s website. About Akero TherapeuticsAkero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical...

TORONTO, Nov. 26, 2021 (GLOBE NEWSWIRE) — Noront Resources Ltd. (TSXV: NOT) (“Noront” or the “Company”) announces that it has amended the shareholder rights plan (the “Rights Plan”) previously adopted on May 26, 2021. The Rights Plan as amended (the “Amended Rights Plan”) is designed to ensure that all Noront shareholders are treated fairly in connection with any take-over bid and to protect against “creeping bids” for the outstanding common shares of Noront (the “Common Shares”) through purchases exempt from applicable take-over bid rules. Specifically, the Amended Rights Plan has been amended to specify that a special meeting of shareholders of Noront to ratify the Amended Rights Plan shall be held on or before May 26, 2022 (the “Meeting”). While...

DENVER, Nov. 26, 2021 (GLOBE NEWSWIRE) — Assure Holdings Corp. (the “Company” or “Assure”) (NASDAQ: IONM; TSXV: IOM), a provider of intraoperative neuromonitoring services, is pleased to announce that the Company intends to complete a non-brokered private placement, with participation by Assure management, the board of directors and certain employees and consultants, of up to 70,300 common shares of the Company (“Common Shares”) at an issue price of US$6.19 per Common Share, for aggregate gross proceeds of up to approximately US$435,000 (the “Offering”). The issue price was determined in the context of the market and in accordance with Nasdaq listing requirements and following the end of the Company’s trading blackout period under its insider trading policy. There are no warrants expected to be issued in connection with the Offering....